Please login to the form below

Not currently logged in
Email:
Password:

New Lipitor indication reimbursements ineligible in South Korea

Pfizer will not make a request to the South Korean government to continue reimbursing Liptor when used for newly approved indications

According to local media reports, a spokesperson for US-based Pfizer has said the company will not make a request to the South Korean government to continue reimbursing Liptor (atorvastatin) when used for newly approved indications.

The spokesperson added that current government policy was unlikely to allow reimbursement for the additional indications of Lipitor, but that the company might change its mind should conditions change.

Pfizer made the decision because it was concerned that the government might cut the price of Lipitor later, if reimbursement coverage were expanded. The South Korean government tends to renegotiate the price of drugs after more indications become eligible for insurance reimbursement.

The Korea Food and Drug Administration (KFDA) recently approved six more indications, including stroke and cardiovascular risk reduction for the world's best-selling drug.

In July 2007, Pfizer projected FY07 Lipitor sales to be flat or down as much as five per cent from USD 12.9bn in FY06.

4th December 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics